Dova Pharmaceuticals Inc. (DOVA:NASDAQ) announced some good news in a press release on June 27, stating: "The U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) that expands the use of DOPTELET (avatrombopag) to include the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment."
The market responded to the news by driving the stock price 35% higher, opening at $14.26 the day after a $10.59 close.
Dr. David Zaccardelli, president and CEO of Dova, commented: "In addition to offering patients with ITP a new treatment option, we expect DOPTELET will also address an important unmet medical need in the market."
For the pharmaceutical company whose stated goal is "acquiring, developing and commercializing drug candidates for diseases where there is a high unmet medical need," the expanded FDA approval is a big win.[NLINSERT]
1) Kevin Jaillet compiled this article for Streetwise Reports LLC and is an employee of Streetwise Reports. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.